Abstract
Insights into immune-mediated thrombotic thrombocytopenic purpura (iTTP) pathophysiology have led to novel targeted therapies. Immunomodulatory strategies target anti-ADAMTS13 antibodies: rituximab is effective in inducing responses in refractory/relapsed TTP and increasing relapse-free survival; caplacizumab targets the von Willebrand factor–platelet interaction to hasten platelet count recovery and reduce mortality and TTP-related ischemic events. Bortezomib and recombinant ADAMTS13 are under investigation. This review examines how targeted therapies are disrupting current treatment paradigms to improve outcomes of iTTP.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 415-420 |
| Number of pages | 6 |
| Journal | Blood |
| Volume | 134 |
| Issue number | 5 |
| DOIs | |
| State | Published - Aug 1 2019 |
Bibliographical note
Publisher Copyright:© 2019 by The American Society of Hematology.
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Fingerprint
Dive into the research topics of 'How targeted therapy disrupts the treatment paradigm for acquired TTP: The risks, benefits, and unknowns'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS